• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors.

作者信息

Wang Xinjing, Wang Wei, Zou Siyi, Xu Zhiwei, Cao Dan, Zhang Shuai, Wei Minzhi, Zhan Qian, Wen Chenlei, Li Fanlu, Chen Hao, Fu Da, Jiang Lingxi, Zhao Ming, Shen Baiyong

机构信息

Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Cell Res. 2024 Sep;34(9):661-664. doi: 10.1038/s41422-024-00990-9. Epub 2024 Jun 24.

DOI:10.1038/s41422-024-00990-9
PMID:38914844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369195/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11369195/a9d4447d3acc/41422_2024_990_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11369195/a9d4447d3acc/41422_2024_990_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11369195/a9d4447d3acc/41422_2024_990_Fig1_HTML.jpg

相似文献

1
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors.KRAS G12V mRNA疫苗与帕博利珠单抗联合治疗：对晚期实体瘤患者的临床疗效
Cell Res. 2024 Sep;34(9):661-664. doi: 10.1038/s41422-024-00990-9. Epub 2024 Jun 24.
2
KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.KRAS G12V 突变通过 TGF-β/EMT 信号通路在上皮细胞样转化促进非小细胞肺癌中 PD-L1 的表达。
Cell Biol Int. 2021 Apr;45(4):795-803. doi: 10.1002/cbin.11524. Epub 2021 Jan 5.
3
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.KRAS G13D 肿瘤突变与接受一线化疗联合或不联合西妥昔单抗治疗的转移性结直肠癌患者结局的关联。
J Clin Oncol. 2012 Oct 10;30(29):3570-7. doi: 10.1200/JCO.2012.42.2592. Epub 2012 Jun 25.
4
Response to first-line pembrolizumab in metastatic -mutated non-small-cell lung cancer.一线帕博利珠单抗治疗转移性 - 突变型非小细胞肺癌的疗效。
Future Oncol. 2024 Mar;20(7):373-380. doi: 10.2217/fon-2023-0952. Epub 2024 Mar 6.
5
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.帕博利珠单抗联合铂类双药方案治疗STK11/KRAS突变的晚期肺腺癌患者获得近乎完全缓解
Clin Lung Cancer. 2022 Mar;23(2):e137-e139. doi: 10.1016/j.cllc.2021.07.007. Epub 2021 Jul 19.
6
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.GI-4000 KRAS疫苗用于治疗I-III期携带KRAS G12C、G12D或G12V突变的肺腺癌患者的II期研究。
Clin Lung Cancer. 2014 Nov;15(6):405-10. doi: 10.1016/j.cllc.2014.06.002. Epub 2014 Jun 21.
7
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.TP53 和 KRAS 共突变可作为鳞状非小细胞肺癌免疫检查点阻断的潜在生物标志物：一例报告。
BMC Med Genomics. 2019 Oct 16;12(1):136. doi: 10.1186/s12920-019-0592-6.
8
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.一种新抗原共享疫苗联合免疫检查点阻断治疗晚期转移性实体瘤的 1 期临床试验中期结果。
Nat Med. 2024 Apr;30(4):1013-1022. doi: 10.1038/s41591-024-02851-9. Epub 2024 Mar 27.
9
Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.基因谱对KRAS突变转移性结直肠癌中抗表皮生长因子受体（EGFR）抗体疗效的影响
Oncol Rep. 2014 Jul;32(1):57-64. doi: 10.3892/or.2014.3179. Epub 2014 May 15.
10
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.联合抑制 DDR1 和 Notch 信号传导是一种针对 KRAS 驱动的肺腺癌的治疗策略。
Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.

引用本文的文献

1
Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data.利用单细胞测序数据筛选肿瘤特异性TCR、表位和HLA亚型的集成系统。
J Immunother Cancer. 2025 Jul 31;13(7):e012029. doi: 10.1136/jitc-2025-012029.
2
Boosting mRNA cancer vaccine efficacy via targeting on macrophages in lymph nodes.通过靶向淋巴结中的巨噬细胞提高mRNA癌症疫苗疗效。
Theranostics. 2025 May 25;15(13):6329-6346. doi: 10.7150/thno.110305. eCollection 2025.
3
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation.

本文引用的文献

1
mRNA-based cancer therapeutics.mRNA 癌症疗法。
Nat Rev Cancer. 2023 Aug;23(8):526-543. doi: 10.1038/s41568-023-00586-2. Epub 2023 Jun 13.
2
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞。
Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10.
3
The landscape of mRNA nanomedicine.信使核糖核酸纳米药物的前景。
肿瘤微环境驱动的非小细胞肺癌免疫治疗耐药性：冷肿瘤向热肿瘤转变的策略
Cancer Drug Resist. 2025 Apr 24;8:21. doi: 10.20517/cdr.2025.14. eCollection 2025.
4
Pancreatic Cancer: Pathogenesis and Clinical Studies.胰腺癌：发病机制与临床研究
MedComm (2020). 2025 Apr 2;6(4):e70162. doi: 10.1002/mco2.70162. eCollection 2025 Apr.
5
KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy.癌症中的KRAS突变：理解免疫调节的信号通路及免疫疗法的潜力
Cancers (Basel). 2025 Feb 25;17(5):785. doi: 10.3390/cancers17050785.
6
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.鉴定介导晚期结直肠癌和胰腺癌中KRAS G12C抑制剂耐药性的候选改变
Clin Cancer Res. 2025 Mar 3;31(5):899-906. doi: 10.1158/1078-0432.CCR-24-2948.
7
Cancer vaccines: current status and future directions.癌症疫苗：现状与未来方向。
J Hematol Oncol. 2025 Feb 17;18(1):18. doi: 10.1186/s13045-025-01670-w.
8
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.靶向Siglec-E可促进肿瘤疫苗诱导的肾癌抗肿瘤免疫。
J Immunother Cancer. 2025 Jan 4;13(1):e010521. doi: 10.1136/jitc-2024-010521.
9
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.RAS 信号通路在肿瘤发生、癌症治疗和耐药机制中的作用。
J Hematol Oncol. 2024 Nov 9;17(1):108. doi: 10.1186/s13045-024-01631-9.
10
Emerging Targets in Non-Small Cell Lung Cancer.非小细胞肺癌的新兴靶点。
Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046.
Nat Med. 2022 Nov;28(11):2273-2287. doi: 10.1038/s41591-022-02061-1. Epub 2022 Nov 10.
4
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.针对致癌 KRAS 突变的 T 细胞靶点的系统发现和验证。
Cell Rep Methods. 2021 Sep 16;1(5):100084. doi: 10.1016/j.crmeth.2021.100084. eCollection 2021 Sep 27.
5
HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people.HLA-A*11:01 限制性 CD8+ T 细胞对土著和非土著人群中甲型流感病毒和乙型流感病毒的免疫反应。
PLoS Pathog. 2022 Mar 7;18(3):e1010337. doi: 10.1371/journal.ppat.1010337. eCollection 2022 Mar.
6
mRNA vaccines for infectious diseases: principles, delivery and clinical translation.传染病的 mRNA 疫苗：原理、传递和临床转化。
Nat Rev Drug Discov. 2021 Nov;20(11):817-838. doi: 10.1038/s41573-021-00283-5. Epub 2021 Aug 25.
7
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.突变 KRAS 表位的生化和功能特征使该癌蛋白成为免疫靶向治疗的有效靶点。
Nat Commun. 2021 Jul 16;12(1):4365. doi: 10.1038/s41467-021-24562-2.
8
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.PD-1 阻断恢复了浸润肿瘤的衰竭 PD-1hiCD39+ CD4 T 细胞的辅助活性。
JCI Insight. 2021 Jan 25;6(2):142513. doi: 10.1172/jci.insight.142513.
9
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.mRNA 疫苗诱导胃肠道癌患者的新抗原特异性 T 细胞免疫。
J Clin Invest. 2020 Nov 2;130(11):5976-5988. doi: 10.1172/JCI134915.
10
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.